Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.
Julie Harper, MD to Present a Rosacea Research Roundup and Pearls
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
POLL: Are You Attending Maui Derm NP+PA Fall 2023?
Journal Digest: September 26
2 Clarke Drive Cranbury, NJ 08512